ChemoCentryx ContactSite Map
About Us

Overview

Senior Management

Board of Directors

Advisory Board

Investors

Contact

Senior Management

Thomas J. Schall, Ph.D.
President, Chief Executive Officer and Chairman of the Board
Dr. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since we commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall's laboratories have been responsible for the discovery or co-discovery of a large percentage of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

^ Return to Top

Markus J. Cappel, Ph.D.
Chief Business Officer and Treasurer
Dr. Cappel has served as our Chief Business Officer since February 2007, and Treasurer since August 2004. From March 2003 to February 2007, he served as our Senior Vice President of Corporate and Business Development. From October 2001 to March 2003, Dr. Cappel served as our Vice President of Business Development. Prior to joining us, Dr. Cappel served as Vice President of Business Development at Alkermes, Inc., a biotechnology company, from 1998 to 2001. Prior to this, he served as Director of Business Development with Millennium Pharmaceuticals as well as in various business development roles at Cygnus, Inc., a biotechnology company. Dr. Cappel received his B.S. in pharmacy and his Ph.D. in pharmaceutics from J.W. Goethe University, Frankfurt, Germany, and his M.B.A. from Harvard Business School. Dr. Cappel also completed postdoctoral studies in pharmaceutics at the University of Michigan.

^ Return to Top

Anne-Marie S. Duliege, M.D., M.S.
Executive Vice President, Chief of Strategic Development and Head of Immuno-Oncology
Dr. Duliege has served as our Executive Vice President, Chief of Strategic Development and Head of Immuno-Oncology since March 2014. From 2004 to 2013, Dr. Duliege served in executive positions in clinical, medical and regulatory affairs at Affymax, Inc., most recently as Chief Medical Officer and Head of Research and Clinical Development. Prior to this, she served as Senior Medical Director at Chiron Corporation in various capacities. Before Chiron, Dr. Duliege was a Senior Research Physician at Genentech Inc. Prior to her career in the pharmaceutical industry, Dr. Duliege was an Epidemiologist with the National Institute of Science and Medical Research in Paris. Dr. Duliege received her M.D. degree and certification in Pediatrics from Paris Medical School, an M.S. in Epidemiology from the Harvard School of Public Health, and an M.S. in Biostatistics from Paris Medical School. Dr. Duliege is an Adjunct Clinical Assistant Professor in Pediatrics at LPCH (Stanford). She also serves on the board of CIRM, the California Institute for Regenerative Medicine and on the board of BayBio.

^ Return to Top

Susan M. Kanaya
Senior Vice President, Finance, Chief Financial Officer and Secretary
Ms. Kanaya has served as our Senior Vice President, Finance, and Chief Financial Officer since January 2006, and Secretary since February 2006. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.

^ Return to Top

Petrus (Pirow) Bekker, M.D., Ph.D.
Chief Medical Officer
Dr. Bekker has served as our Chief Medical Officer since September 2014. From February 2009 to September 2014, Dr. Bekker served as our Senior Vice President of Clinical and Medical Affairs since February 2009. From April 2005 to February 2009, Dr. Bekker served as our Vice President of Clinical and Medical Affairs. Prior to joining us, Dr. Bekker worked at Amgen Inc., where he served as Senior Director of Global Safety from July 2004 to April 2005 and as Senior Director of Clinical Development and Director of Clinical Development from December 1997 to July 2004. Prior to this, he served as a clinical researcher and scientist at Procter & Gamble Pharmaceuticals in various capacities for seven years. Dr. Bekker received his Ph.D. in molecular biology from Pennsylvania State University and his M.D. and medical training in South Africa at the University of Pretoria.

^ Return to Top

Israel F. Charo, M.D., Ph.D.
Senior Vice President of Research
Dr. Charo has served as our Senior Vice President of Research since September 2014 and was a member of our Scientific Advisory Board until that time. Prior to joining us, Dr. Charo was a Scientist-in-Residence at Bay City Capital since 2009. Dr. Charo is also a Senior Investigator at the Gladstone Institute of Cardiovascular Disease, and Professor of Medicine at UCSF. He studies the role of chemokines in leukocyte trafficking and inflammation. His group cloned the chemokine receptor known as CCR2, and showed that it is a major driver for the recruitment of monocyte/macrophages to developing atherosclerotic lesions. Prior to that, Dr. Charo was one of the founding scientists of COR Therapeutics (subsequently acquired by Millennium), where he was part of the team that developed the platelet inhibitor Integrilin. Dr. Charo received his M.D.-Ph.D. From SUNY Downstate in New York, and is trained in internal medicine (The New York Hospital, Weill Medical Center) and Rheumatology (UCSF). His undergraduate (SUNY Stony Brook, NY) and Master's (UC Berkeley) degrees are in Engineering and Materials Science.

^ Return to Top